- Psyence Group (CSE:PSYG) has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency
- The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis
- Psyence has partnered with a psychedelic contract research organization, Clerkenwell Health, to design and deliver the clinical trial at two centres in the United Kingdom
- Psyence CEO, Dr. Neil Maresky, sat down with Daniella Atkinson to discuss the news
- Psysence Group Inc. (PSYG) opened trading at C$0.10 per share
Psyence Group (CSE:PSYG) has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA).
This is the UK’s equivalent regulatory body to Canada’s Health Canada and the US’s FDA. The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis.
Psyence has partnered with a psychedelic contract research organization, Clerkenwell Health, to design and deliver the clinical trial at two centres in the United Kingdom.
Psyence CEO Dr. Neil Maresky sat down with Daniella Atkinson to discuss the news.
“It is a privilege to conduct research with psilocybin that may result in significant improvements in patients’ lives. We are thrilled that we can now progress this important trial.”
Psyence is a public life science biotechnology company with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Pysence operates one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Lesotho, Southern Africa.
Psysence Group Inc. (PSYG) opened trading at C$0.10 per share.
